Safety

Company Announcement

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Roche Diagnostics to Replace CoaguChek® XS PT Test Strips

For Immediate Release

October 31, 2018

Contact

Consumers

800-428-4674

Media

Nicole Clark
Communications Business Partner
nicole.clark@roche.com
(515) 559-5770

Announcement

This notification supplements previous Urgent Medical Device Correction (UMDC) communications initially issued by Roche Diagnostics on September 12, 2018 and updated on October 17, 2018.

Roche Diagnostics will be proactively replacing all CoaguChek XS PT Test Strips in the United States.

  • Patient Self-Testers (PST) will receive replacement test strips from their self-testing service providers.
  • Professional / Healthcare Providers will receive their replacement test strips through Roche.

The affected CoaguChek XS PT Test Strips are used with the following CoaguChek professional and patient self-testing point-of-care meters listed in the table below.


Healthcare Providers (professional)

Patient Self-Testers

CoaguChek XS Professional

CoaguChek XS PST

CoaguChek XS Pro

CoaguChek Vantus

CoaguChek XS Plus

 

Roche Diagnostics, the manufacturer of CoaguChek meters and test strips, recently calibrated the CoaguChek XS PT Test Strips to the most recent International Normalized Ratio (INR) Standard. Since calibrating to this new standard, Roche Diagnostics has been informed of patients experiencing inaccurately high INR test results when testing with the affected lots of CoaguChek XS PT Test Strips listed in the table below.


Product

Catalog
numbers

Affected lot numbers

CoaguChek XS PT Test
2x24 Strips

04625315160

28124111
28124121
28631911
28631921
28631924
28632021
28632213
28632312
28632412
29415113
29415123
29494221
29494312
29494613
29494711
29778721
29779012
29779213
29779214
30497213
30497311
30497413

30497423
30497515
31404314
31404821
32264116
32264212
32264316
32264317
32264411
32264421
33045913
33046011
33046113
33046312
33046314
33046321
33046322
33449612
33449712
33449723
33449817

CoaguChek XS PT Test
6 Strips

04625374160

CoaguChek XS Test 24
Tests USA

07797826160

The lot number is printed on the test strip label, which is applied to the test strip vial.  See the picture below for an example of the location of the lot number on the test strip vial. 

Patients taking warfarin who receive inaccurate INR results above their target therapeutic range may be at risk for inappropriate therapeutic measures such as a warfarin dose reduction, interruption of warfarin use, or administration of vitamin K. 

The affected test strips in the table above will be replaced with new CoaguChek XS PT Test Strips, which are not impacted by the Urgent Medical Device Correction (UMDC) and can be used without the need for confirmatory measurements with a laboratory method.

Action Required – Patient Self-Testers:
Stop using and discard any CoaguChek XS PT Test Strips listed in the table above.  As of October 29, 2018, Roche started shipping newly calibrated test strips to healthcare providers and patient self-testing service providers. These test strips have been calibrated to the previous INR standard. For questions regarding when you will receive your new test strips, please contact your test strip provider. If you have any questions regarding your testing schedule, please contact your healthcare provider.

Action Required – Health Care Providers:
Stop using and discard any CoaguChek XS PT Test Strips listed in the table above. Also, please advise your self-testing patients to do the same (see above). Roche Diagnostics has started shipping unaffected test strips to healthcare providers, patient self-testing service providers and distribution partners.

Roche Diagnostics is notifying its healthcare providers, patient self-testing service providers, and distribution partner customers to arrange for replacement of all affected CoaguChek XS PT Test Strips listed in the table above. This will be executed through an updated Urgent Medical Device Correction (UMDC).

Healthcare providers and patients (self-testing customers) with questions may contact Roche Diagnostics Point of Care Technical Service by telephone at 1-800-428-4674.

Adverse reactions or quality problems experienced with the use of this product may be reported to Roche Diagnostics Point of Care Technical Service at 1-800-428-4674 and the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Nicole Clark
Communications Business Partner
Roche Diagnostics Corporation
(317) 361-9512
nicole.clark@roche.com

###

Product Photos

  • CoaguChek XS PT Test Strips label showing lot number location on the test strip vial

Page Last Updated: 11/17/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English